USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility from 6th - 17th February, 2023, Cipla said in an exchange filing.
On conclusion of the inspection, the company has received 8 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, Cipla said.
At 09:23 AM; Cipla quoted 5 per cent lower at Rs 971.60, as compared to 0.16 per cent rise in the S&P BSE Sensex. The stock of pharmaceutical company was trading at its lowest level since July 2022.
In past one month, Cipla has underperformed the market, by falling 11 per cent, as against 1 per cent gain in the benchmark index.
Meanwhile, after announcement of October-December quarter (Q3FY23) earnings by Cipla on January 26, analysts at Prabhudas Lilladher reduced their FY24/FY25 earnings by ~4 per cent factoring in delay in key US launches and lower margins.
“Cipla’s Q3FY23 EBITDA was largely in-line with our estimates (24 per cent) aided by higher GMs and strong US sales. We expect 18 per cent EPS CAGR over FY23-25E given resilient earnings, improving US visibility and strong free cash flow generation,” the brokerage firm said.
Analysts further said they continue to remain positive on Cipla’s growth across key segments including India and US given strong traction in respiratory and other portfolio, ExCOVID, domestic formulation to potentially grow +10 per cent going forward and sustainability of current US revs, backed by potential key launches.
Great minds don’t just skim the surface, they uncover the full story.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 premium stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app